Cohort Studyhigh evidence
Interleukin-6 is a mediator of therapeutic efficacy in acute lung injury.
American journal of respiratory and critical care medicine·April 28, 2026·PMID 42150114
Why it mattersIdentifying IL-6 as a mediator of treatment effect provides a mechanistic rationale for monitoring IL-6 in critical care and supports targeting inflammation in ARDS and COVID-19. It helps clinicians interpret why certain interventions work and may guide future therapeutic strategies.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled